CHIR-98014

• UNSPSC Description:

  CHIR-98014 is a potent, cell-permeable GSK-3 inhibitor with IC50s of 0.65 and 0.58 nM for GSK-3α and GSK-3β, respectively; it shows less potent activities against cdc2 and erk2.

• Target Antigen:

  GSK-3

• Type:

  Reference compound

• Related Pathways:

  PI3K/Akt/mTOR;Stem Cell/Wnt

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/CHIR-98014.html

• Purity:

  98.0

• Solubility:

  DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  ClC1=CC(Cl)=CC=C1C2=NC(NCCNC3=CC=C([N+]([O-])=O)C(N)=N3)=NC=C2N4C=CN=C4

• Molecular Weight:

  486.31

• References & Citations:

  [1]Ring DB, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.|[2]Naujok O, et al. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors. BMC Res Notes. 2014 Apr 29;7:273.|[3]Zajkowski T, et al. Stabilization of microtubular cytoskeleton protects neurons from toxicity of N-terminal fragment of cytosolic prion protein. Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2228-39.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  252935-94-7